nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

01.11.2008 | Retinal Disorders

Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration

verfasst von: S. Y. Cohen, D. Bremond-Gignac, G. Quentel, G. Mimoun, T. Citterio, S. Bisot-Locard, A. Beresniak

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 11/2008

Einloggen, um Zugang zu erhalten

Abstract

Aims

To assess effectiveness, cost, and cost-effectiveness of ranibizumab versus the current medical practices of treating age-related macular degeneration in France.

Methods

A simulation decision framework over 1 year compared ranibizumab versus the usual care using two effectiveness criteria: the “visual acuity improvement rate” (greater than 15 letters on the ETDRS scale) and the “rate of legal blindness avoided”. Two decision trees included various sequences of current treatments, with or without ranibizumab.

Results

Ranibizumab appeared significantly more effective than the usual care (p < 0.001), providing greater treatment success rate of visual acuity improvement (48.8% versus 33.9%). The cost of the ranibizumab strategy was higher (9,123 euros (€) over 1 year for ranibizumab versus 7,604 € for the usual care) but the average cost-effectiveness was lower – 18,721 € /success for ranibizumab versus 22,543 €/success for usual care (p < 0.001). Considering the “legal blindness avoided” success criterion, the ranibizumab strategy appeared significantly more effective (p < 0.001), providing greater treatment success rate for of legal blindness avoided than usual care (99.7% versus 93.1%) although it was more expensive (9,196 € over 1 year for ranibizumab versus 5,713 € for the usual care).

Conclusion

Ranibizumab significantly improved the rate of visual acuity improvement and reduced the rate of legal blindness. Ranibizumab appeared significantly more cost-effective than the usual treatments in terms of visual acuity improvement.

Chaine G, Rohart C (2007) Epidemiology and risk factors for age-related macular degeneration. J Fr Ophtalmol 30:74CrossRef

Ambati J, Ambati B, Yoo S, Ianchulev S, Adamis A (2003) Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48:257–293PubMedCrossRef

Ferris FL, Fine SL, Hyman L (1984) Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 102(11):1640–1642 NovPubMedCrossRef

Pina JP, Offret H, Labetoulle M (2007) Les nouveaux traitements de la DMLA. Medecine 3(10):443–445

Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report. Arch Ophthalmol 117:1329–1345

Rosenfeld PJ, Heier JS, Hantsbatger G, Shams N (2006) Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 113:632CrossRef

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, for the Marina Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. New Eng J Med 355:1419–1431PubMedCrossRef

Bradley J, Ju M, Robinson GS (2007) Combination therapy for the treatment of ocular neovascularization. Angiogenesis 10:141–148PubMedCrossRef

Rajczi A (2007) A critique of the innovation argument against a national health program. Bioethics 21(6):316–323 JulPubMedCrossRef

10.

Weinstein MC (2006) Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 24(11):1043–1053PubMedCrossRef

11.

Polsky D, Glick HA, Wilke R, Schulman K (1997) Confidence Intervals for cost-effectiveness ratios: a comparison of four methods. Health Econ 6:243–252PubMedCrossRef

12.

Kegan B, West RW (2005) Modeling the simple epidemic with deterministic differential equations and random initial conditions. Math Biosci 195(2):179–193PubMedCrossRef

13.

Takeda AL, Colquitt JL, Clegg AJ, Jones J (2007) Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br J Ophthalmol 91(9):1177–1182PubMedCrossRef

14.

Rosenfeld PJ, Rich RM, Lalwani GA (2006) Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 19:361–372PubMed

15.

Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N (2006) Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 113(4):642.e1–4. Epub 2006 Feb 14.CrossRef

16.

Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group (2007) Angiographic and Optical Coherence Tomographic Results of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology 11

17.

VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupD’Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B (2006) Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113(6):992–1001PubMedCrossRef

18.

Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D’Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD (2005) Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112(10):1747–1757PubMedCrossRef

19.

Macugen AMD Study Group (2007) Pegaptanib 1-Year Systemic Safety Results from a Safety-Pharmacokinetic Trial in Patients with Neovascular Age-Related Macular Degeneration. Ophthalmology 114(9):1702–1712CrossRef

20.

Schmidt-Erfurth U (1998) Photodynamic therapy. Minimally invasive treatment of choroidal neovascularisation. Ophthalmology 95:725–731CrossRef

21.

Kaiser PK (2006) Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open label extension. Graefe Arch Clin Exp Ophthalmol 244:1132–1142CrossRef

22.

Liggett PE, Colina J, Chaudhry NA, Tom D, Haffner G (2006) Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 142(6):1072–1074PubMedCrossRef

23.

Brown MM, Brown GC, Stein JD, Roth Z, Campanella J, Beauchamp GR (2005) Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol 40(3):277–287PubMed

24.

Brown GC, Brown MM, Brown H, Godshalk AN (2007) Pharmacoeconomics and macular degeneration. Curr Opin Ophthalmol 18(3):206–211PubMedCrossRef

25.

Raftery J, Clegg A, Jones J, Tan SC, Lotery A (2007) Ranibizumab (lucentis) versus bevacizumab (avastin): modelling cost effectiveness. Br J Ophthalmol 91(9):1244–1246PubMedCrossRef

26.

Duru G, Auray JP, Beresniak A, Lamure M, Paine A, Nicoloyannis N (2002) Limitations of the methods used for calculating quality-adjusted life years values. Pharmacoeconomics 20(7):463–473PubMedCrossRef

27.

McGregor M, Caro JJ (2006) QALYs: are they helpful to decision-makers? Pharmacoeconomics 24(10):947–952PubMedCrossRef

28.

Bremond-Gignac D, Tixier J, Missotten T, Laroche L, Beresniak A (2002) Evaluation of the quality of life in ophthalmology. Presse Med 19;31(34):1607–1612

Titel: Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration
verfasst von: S. Y. Cohen
D. Bremond-Gignac
G. Quentel
G. Mimoun
T. Citterio
S. Bisot-Locard
A. Beresniak
Publikationsdatum: 01.11.2008
Verlag: Springer-Verlag
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 11/2008
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-008-0890-8

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

CME: Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Wird ein Glaukom chirurgisch behandelt, ist die anschließende Wundheilung von entscheidender Bedeutung. In diesem CME-Kurs lernen Sie, welche Pathomechanismen der Vernarbung zugrunde liegen, wie perioperativ therapiert und Operationsversagen frühzeitig erkannt werden kann.

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration

Abstract

Aims

Methods

Results

Conclusion

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

CME: Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Aims

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2008

German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye

A review of in vivo animal studies in retinal prosthesis research

Comparison of visual function in pigmented and albino rats by electroretinography and visual evoked potentials

Ciliary body melanoma with partial deletion of chromosome 3 detected with multiplex ligation-dependent probe amplification

Intravitreal injection of bevacizumab and gas for diabetic premacular hemorrhage with active fibrovascular proliferation

Cultivation of an immortalized human corneal endothelial cell population and two distinct clonal subpopulations on thermo-responsive carriers

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Staging und Systemtherapie bei okulären und periokulären Metastasen

CME: Wundheilung nach Trabekulektomie

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Update Augenheilkunde